Tang Cam Phung Pham1, Kirstine Nyvold Bojsen-Møller2,3, Sten Madsbad2, Jørgen Frank Pind Wojtaszewski1, Erik Arne Richter1, Lykke Sylow4. 1. Section of Molecular Physiology, Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark. 2. Department of Endocrinology, Hvidovre Hospital, Hvidovre, Denmark. 3. Novo Nordisk Foundation Centre for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark. 4. Section of Molecular Physiology, Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark. Lshansen@nexs.ku.dk.
Abstract
BACKGROUND: Roux-en-Y gastric bypass (RYGB) surgery is a therapeutic intervention for morbid obesity and type 2 diabetes (T2D) that improves metabolic regulation. Follistatin (Fst) could be implicated in improved glycemia as it is highly regulated by RYGB. However, it is unknown if metabolic status, such as T2D, alters the Fst response to RYGB. In addition, the effect of RYGB on the Fst target, activin A, is unknown in individuals with obesity and T2D, but is needed to interpret the functional effects of altering Fst. Finally, whether Fst-regulated intracellular signaling contributes to beneficial effects of RYGB is undetermined. METHODS: Circulating Fst and activin A were measured before, 1 week, and 1 year after RYGB surgery in a total of 20 individuals with obesity, 10 with normoglycemia (NGT) and 10 with preoperative T2D. Intracellular signaling downstream of the Activin receptor type IIB (ActRIIB) signaling pathway was analyzed in skeletal muscle and adipose tissue. RESULTS: The doubling in circulating Fst observed in subjects with NGT 1-week and 1-year post surgery was absent in T2D. After 1 week, RYGB reduced activin A by 27% (p < 0.001) and 20% (p < 0.01) in subjects with NGT and T2D, respectively; a reduction that tended to be maintained in the subjects with T2D at 1-year post-RYGB (-15%; p = 0.0592). RYGB had no effects on skeletal muscle ActRIIB signaling. In contrast, adipose tissue phosphorylation of SMAD2Ser465/467, p70S6KThr389, S6RPSer235/236, and 4E-BP1Thr37/49 was highly regulated, particularly 1-year post-RYGB (p < 0.05). CONCLUSIONS: In subjects with preoperative T2D, RYGB did not increase circulating Fst contrasting subjects with NGT, while the reduction in activin A was maintained. ActRIIB signaling was upregulated in adipose tissue, but not skeletal muscle, following RYGB in both individuals with NGT and T2D. Our results suggest a role of adipose tissue ActRIIB signaling for the beneficial effects of RYGB surgery.
BACKGROUND: Roux-en-Y gastric bypass (RYGB) surgery is a therapeutic intervention for morbid obesity and type 2 diabetes (T2D) that improves metabolic regulation. Follistatin (Fst) could be implicated in improved glycemia as it is highly regulated by RYGB. However, it is unknown if metabolic status, such as T2D, alters the Fst response to RYGB. In addition, the effect of RYGB on the Fst target, activin A, is unknown in individuals with obesity and T2D, but is needed to interpret the functional effects of altering Fst. Finally, whether Fst-regulated intracellular signaling contributes to beneficial effects of RYGB is undetermined. METHODS: Circulating Fst and activin A were measured before, 1 week, and 1 year after RYGB surgery in a total of 20 individuals with obesity, 10 with normoglycemia (NGT) and 10 with preoperative T2D. Intracellular signaling downstream of the Activin receptor type IIB (ActRIIB) signaling pathway was analyzed in skeletal muscle and adipose tissue. RESULTS: The doubling in circulating Fst observed in subjects with NGT 1-week and 1-year post surgery was absent in T2D. After 1 week, RYGB reduced activin A by 27% (p < 0.001) and 20% (p < 0.01) in subjects with NGT and T2D, respectively; a reduction that tended to be maintained in the subjects with T2D at 1-year post-RYGB (-15%; p = 0.0592). RYGB had no effects on skeletal muscle ActRIIB signaling. In contrast, adipose tissue phosphorylation of SMAD2Ser465/467, p70S6KThr389, S6RPSer235/236, and 4E-BP1Thr37/49 was highly regulated, particularly 1-year post-RYGB (p < 0.05). CONCLUSIONS: In subjects with preoperative T2D, RYGB did not increase circulating Fst contrasting subjects with NGT, while the reduction in activin A was maintained. ActRIIB signaling was upregulated in adipose tissue, but not skeletal muscle, following RYGB in both individuals with NGT and T2D. Our results suggest a role of adipose tissue ActRIIB signaling for the beneficial effects of RYGB surgery.
Authors: Philip R Schauer; Deepak L Bhatt; John P Kirwan; Kathy Wolski; Ali Aminian; Stacy A Brethauer; Sankar D Navaneethan; Rishi P Singh; Claire E Pothier; Steven E Nissen; Sangeeta R Kashyap Journal: N Engl J Med Date: 2017-02-16 Impact factor: 91.245
Authors: Peter H Albers; Kirstine N Bojsen-Møller; Carsten Dirksen; Annette K Serup; Dorte E Kristensen; Jan Frystyk; Trine R Clausen; Bente Kiens; Erik A Richter; Sten Madsbad; Jørgen F P Wojtaszewski Journal: Am J Physiol Regul Integr Comp Physiol Date: 2015-06-10 Impact factor: 3.619
Authors: Janaiah Kota; Chalonda R Handy; Amanda M Haidet; Chrystal L Montgomery; Amy Eagle; Louise R Rodino-Klapac; Danielle Tucker; Christopher J Shilling; Walter R Therlfall; Christopher M Walker; Steven E Weisbrode; Paul M L Janssen; K Reed Clark; Zarife Sahenk; Jerry R Mendell; Brian K Kaspar Journal: Sci Transl Med Date: 2009-11-11 Impact factor: 17.956
Authors: Jerry R Mendell; Zarife Sahenk; Samiah Al-Zaidy; Louise R Rodino-Klapac; Linda P Lowes; Lindsay N Alfano; Katherine Berry; Natalie Miller; Mehmet Yalvac; Igor Dvorchik; Melissa Moore-Clingenpeel; Kevin M Flanigan; Kathleen Church; Kim Shontz; Choumpree Curry; Sarah Lewis; Markus McColly; Mark J Hogan; Brian K Kaspar Journal: Mol Ther Date: 2017-03-06 Impact factor: 11.454
Authors: Tania Garito; Ronenn Roubenoff; Marcus Hompesch; Linda Morrow; Katherine Gomez; Daniel Rooks; Charles Meyers; Monte S Buchsbaum; Srikanth Neelakantham; Therese Swan; Lee Anne Filosa; Didier Laurent; Olivier Petricoul; Marjorie Zakaria Journal: Diabetes Obes Metab Date: 2017-08-02 Impact factor: 6.577
Authors: Kirstine N Bojsen-Møller; Carsten Dirksen; Nils B Jørgensen; Siv H Jacobsen; Annette K Serup; Peter H Albers; Dorte L Hansen; Dorte Worm; Lars Naver; Viggo B Kristiansen; Jørgen F P Wojtaszewski; Bente Kiens; Jens J Holst; Erik A Richter; Sten Madsbad Journal: Diabetes Date: 2013-11-15 Impact factor: 9.461
Authors: Christoffer Clemmensen; Timo D Müller; Stephen C Woods; Hans-Rudolf Berthoud; Randy J Seeley; Matthias H Tschöp Journal: Cell Date: 2017-02-23 Impact factor: 41.582
Authors: Patricio V Sepulveda; Séverine Lamon; Adam Hagg; Rachel E Thomson; Catherine E Winbanks; Hongwei Qian; Clinton R Bruce; Aaron P Russell; Paul Gregorevic Journal: Sci Rep Date: 2015-12-11 Impact factor: 4.379